Cargando…
Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy
Background Pleural infection is a common clinical problem resulting in prolonged hospitalization and increased mortality. In patients with active malignancy, management decisions are based on the need for further immunosuppressive therapies, the ability to tolerate surgery, and consideration of the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184713/ https://www.ncbi.nlm.nih.gov/pubmed/37197128 http://dx.doi.org/10.7759/cureus.37545 |
_version_ | 1785042198299934720 |
---|---|
author | Salahuddin, Moiz Ost, David Hwang, Hyunsoo Jimenez, Carlos Saltijeral, Sahara Eapen, George Casal, Roberto Sabath, Bruce Lin, Julie Cerrillos, Eben Nevárez Tinoco, Tamara Grosu, Horiana |
author_facet | Salahuddin, Moiz Ost, David Hwang, Hyunsoo Jimenez, Carlos Saltijeral, Sahara Eapen, George Casal, Roberto Sabath, Bruce Lin, Julie Cerrillos, Eben Nevárez Tinoco, Tamara Grosu, Horiana |
author_sort | Salahuddin, Moiz |
collection | PubMed |
description | Background Pleural infection is a common clinical problem resulting in prolonged hospitalization and increased mortality. In patients with active malignancy, management decisions are based on the need for further immunosuppressive therapies, the ability to tolerate surgery, and consideration of the limited life expectancy. Identifying patients at risk for death or poor outcomes is very important as it will guide care. Study design and methods This is a retrospective cohort study of all patients with active malignancy and empyema. The primary outcome was time to death from empyema at three months. The secondary outcome was surgery at 30 days. Standard Cox regression model and cause-specific hazard regression model were used to analyze the data. Results A total of 202 patients with active malignancy and empyema were included. The overall mortality rate at three months was 32.7%. On multivariable analysis, female gender and higher urea were associated with an increased risk of death from empyema at three months. The area under the curve (AUC) of the model was 0.70. The risk factors for surgery at 30 days included the presence of frank pus and postsurgical empyema. The AUC of the model was 0.76. Interpretation Patients with active malignancy and empyema have a high probability of death. In our model, the risk factors for death from empyema included female gender and higher urea. |
format | Online Article Text |
id | pubmed-10184713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-101847132023-05-16 Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy Salahuddin, Moiz Ost, David Hwang, Hyunsoo Jimenez, Carlos Saltijeral, Sahara Eapen, George Casal, Roberto Sabath, Bruce Lin, Julie Cerrillos, Eben Nevárez Tinoco, Tamara Grosu, Horiana Cureus Infectious Disease Background Pleural infection is a common clinical problem resulting in prolonged hospitalization and increased mortality. In patients with active malignancy, management decisions are based on the need for further immunosuppressive therapies, the ability to tolerate surgery, and consideration of the limited life expectancy. Identifying patients at risk for death or poor outcomes is very important as it will guide care. Study design and methods This is a retrospective cohort study of all patients with active malignancy and empyema. The primary outcome was time to death from empyema at three months. The secondary outcome was surgery at 30 days. Standard Cox regression model and cause-specific hazard regression model were used to analyze the data. Results A total of 202 patients with active malignancy and empyema were included. The overall mortality rate at three months was 32.7%. On multivariable analysis, female gender and higher urea were associated with an increased risk of death from empyema at three months. The area under the curve (AUC) of the model was 0.70. The risk factors for surgery at 30 days included the presence of frank pus and postsurgical empyema. The AUC of the model was 0.76. Interpretation Patients with active malignancy and empyema have a high probability of death. In our model, the risk factors for death from empyema included female gender and higher urea. Cureus 2023-04-13 /pmc/articles/PMC10184713/ /pubmed/37197128 http://dx.doi.org/10.7759/cureus.37545 Text en Copyright © 2023, Salahuddin et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Infectious Disease Salahuddin, Moiz Ost, David Hwang, Hyunsoo Jimenez, Carlos Saltijeral, Sahara Eapen, George Casal, Roberto Sabath, Bruce Lin, Julie Cerrillos, Eben Nevárez Tinoco, Tamara Grosu, Horiana Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy |
title | Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy |
title_full | Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy |
title_fullStr | Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy |
title_full_unstemmed | Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy |
title_short | Clinical Risk Factors for Death in Patients With Empyema and Active Malignancy |
title_sort | clinical risk factors for death in patients with empyema and active malignancy |
topic | Infectious Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184713/ https://www.ncbi.nlm.nih.gov/pubmed/37197128 http://dx.doi.org/10.7759/cureus.37545 |
work_keys_str_mv | AT salahuddinmoiz clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy AT ostdavid clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy AT hwanghyunsoo clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy AT jimenezcarlos clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy AT saltijeralsahara clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy AT eapengeorge clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy AT casalroberto clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy AT sabathbruce clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy AT linjulie clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy AT cerrilloseben clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy AT nevareztinocotamara clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy AT grosuhoriana clinicalriskfactorsfordeathinpatientswithempyemaandactivemalignancy |